Literature DB >> 1969718

Is the site of action of ketamine anesthesia the N-methyl-D-aspartate receptor?

T Yamamura1, K Harada, A Okamura, O Kemmotsu.   

Abstract

Synaptic mechanisms underlying ketamine anesthesia were studied using in vitro preparations of the lamprey CNS. Although lampreys are one of the most primitive vertebrates, the synaptic physiology and pharmacology are similar to those in the higher vertebrates. Axonal conduction, transmitter release from the presynaptic terminal, postsynaptic response to the putative neurotransmitters, and resting and activated membrane properties were studied in the absence and the presence of various concentrations of ketamine. Ketamine markedly reduced N-methyl-D-aspartate (NMDA)-activated responses, such as depolarizations to bath-applied NMDA and bursting rhythm during "fictive locomotion." The 50% block of the responses took place in the presence of 10-20 microM ketamine, whereas those induced by kainate and quisqualate (the other two subclasses of L-glutamate/L-aspartate agonists) were spared at concentrations higher than 600-800 microM. None of the other neuronal events tested were suppressed in the presence of still higher concentrations of ketamine. The results support the hypothesis that ketamine might exert its anesthetic effect by a pharmacologically specific interaction with the NMDA receptor.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1969718     DOI: 10.1097/00000542-199004000-00021

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  33 in total

1.  Ketamine impairs excitability in superficial dorsal horn neurones by blocking sodium and voltage-gated potassium currents.

Authors:  Rose Schnoebel; Matthias Wolff; Saskia C Peters; Michael E Bräu; Andreas Scholz; Gunter Hempelmann; Horst Olschewski; Andrea Olschewski
Journal:  Br J Pharmacol       Date:  2005-11       Impact factor: 8.739

2.  Inhibitory and excitatory response areas of neurons in the central nucleus of the inferior colliculus in unanesthetized chinchillas.

Authors:  Ala Alkhatib; Ulrich W Biebel; Jean W T Smolders
Journal:  Exp Brain Res       Date:  2006-03-31       Impact factor: 1.972

3.  Repeated SKF 38393 and nigrostriatal system neuronal responsiveness: functional down-regulation is followed by up-regulation after withdrawal.

Authors:  M D Kelland; D K Pitts; A S Freeman; L A Chiodo
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-05       Impact factor: 3.000

4.  The Epidural and Intrathecal Administration of Ketamine.

Authors: 
Journal:  Curr Rev Pain       Date:  1999

5.  Inhibition by anaesthetics of 14C-guanidinium flux through the voltage-gated sodium channel and the cation channel of the 5-HT3 receptor of N1E-115 neuroblastoma cells.

Authors:  M Barann; M Göthert; K Fink; H Bönisch
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-02       Impact factor: 3.000

6.  Neonatal exposure of ketamine inhibited the induction of hippocampal long-term potentiation without impairing the spatial memory of adult rats.

Authors:  Dongyong Guo; Jianhui Gan; Tao Tan; Xin Tian; Guolin Wang; Kevin Tak-Pan Ng
Journal:  Cogn Neurodyn       Date:  2018-02-22       Impact factor: 5.082

7.  Volatile anesthetics inhibit NMDA-stimulated 45Ca uptake by rat brain microvesicles.

Authors:  R S Aronstam; D C Martin; R L Dennison
Journal:  Neurochem Res       Date:  1994-12       Impact factor: 3.996

8.  Effects of intravenous ketamine on gastrointestinal motility in the dog.

Authors:  J Fass; R Bares; V Hermsdorf; V Schumpelick
Journal:  Intensive Care Med       Date:  1995-07       Impact factor: 17.440

9.  The N-methyl-D-aspartate (NMDA) receptor antagonist dizocilpine (MK-801) suppresses enflurane-induced opisthotonus in mice.

Authors:  H Komatsu; J Nogaya; D Anabuki; K Ogli
Journal:  J Anesth       Date:  1993-10       Impact factor: 2.078

10.  Does propofol enhance GABA-mediated inhibition?

Authors:  H Otsuka; T Yamamura; Y Hanaoka; O Kemmotsu
Journal:  J Anesth       Date:  1992-07       Impact factor: 2.078

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.